key: cord-1038895-7jz20zh0
authors: Chen, Ji‐Ming
title: Live unattenuated vaccines for controlling viral diseases including COVID‐19
date: 2020-08-24
journal: J Med Virol
DOI: 10.1002/jmv.26453
sha: 291c26693f51a0ca4ca5278709b0840f8047819c
doc_id: 1038895
cord_uid: 7jz20zh0

Live unattenuated vaccines (LUVs) have been neglected for decades due to widespread prejudice against their safety, although they have successfully controlled yellow fever and adenovirus infection in humans as well as rinderpest and infectious bursal disease in animals. This review elucidated that LUVs could be highly safe with selective use of neutralizing anti‐virus antibodies, natural anti‐glycan antibodies, non‐antibody antivirals, and ectopic inoculation. Also, LUVs could be of high efficacy, high development speed, and high production efficiency, with the development of humanized monoclonal antibodies and other modern technologies. They could circumvent antibody‐dependent enhancement and maternal‐derived antibody interference. With these important advantages, LUVs could be more powerful than other vaccines for controlling some viral diseases, and they warrant urgent investigation with animal experiments and clinical trials for defeating the COVID‐19 pandemic caused by the novel coronavirus SARS‐CoV‐2. This article is protected by copyright. All rights reserved.

The whole world is eagerly waiting for safe and effective vaccines to control the COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2. [1] [2] [3] However, there could be multiple pitfalls for development of a qualified COVID-19 vaccine, as indicated by decades of research on vaccines against animal coronaviruses and other human coronaviruses. 4, 5 Vaccines for viral diseases include whole-virus vaccines and subunit vaccines. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Whole-virus vaccines harbour live vaccines and inactivated vaccines, and subunit vaccines rely on virion subunits presented by proteins,

Like LAVs, LUVs inhibit viral replication and thus minimize viral pathogenesis and save time for the rising of acquired immunity. Unlike LAVs which rely on genomic mutations to inhibit viral replication, LUVs inhibit viral replication through one or more mechanisms other than genomic changes, as shown in Figure 1 . anti-glycan antibodies, non-antibody antivirals, or ectopic inoculation.

This mechanism was discovered one century ago, and possibly began with the control of rinderpest, which caused many deaths of cattle and buffalo worldwide six decades ago. 18, 19 In the 1890s, Russian and South African scientists independently discovered that antibody-containing immune serum taken from recovered animals and virus-containing blood taken from infected animals, when given simultaneously, could safely induce long-term immunity to rinderpest. This led to the birth of the AVA LUV for rinderpest, and application of this vaccine eliminated rinderpest from southern Africa in 1905 and Russia in 1928. 18, 19 Later, this LUV was replaced with an LAV not requiring immune sera for production. Limited supply of neutralizing AVA or immune sera has thwarted the application of AVA LUVs for long. [16] [17] [18] [19] As elucidated below, humanized monoclonal antibodies (mAbs) can solve this problem and rejuvenate AVA LUVs.

Another AVA LUV was used successfully in controlling yellow fever in the 1930s. 16, 17 Yellow fever is endemic in many countries in Africa and America for centuries, and causes ∼30,000 deaths annually in recent years. 16 The LUC virus was a neurotropic strain which grew in mouse brains and could cause severe systemic infection and encephalitis. 16 The LUV was prepared by mixing the live virus with immune serum collected from recovered people. A researcher was first inoculated with this vaccine in 1931. He was working at the Rockefeller Institute where five researchers had died of the disease for developing yellow fever vaccines. He was hospitalized under strict isolation after the inoculation, and he did not show any symptoms. Then his colleagues at the Rockefeller Institute were all vaccinated with the vaccine, and safely obtained adequate immunity against the deadly disease. Then, this vaccine was safely used in the Western Hemisphere and England for several years. 16 Later, this LUV was replaced with an LAV not requiring immune sera for production. 16, 17 Currently, an AVA LUV has been used successfully from the 1990s for the control of infectious bursal disease, an economically important disease that affects chickens worldwide. 20, 21 This LUV is a cocktail of a live pathogenic infectious bursal disease virus (IBDV) mixed with anti-IBDV antibodies derived from hyperimmunized chicken sera. It is administered subcutaneously to day-old chicks even in the presence of maternally-derived antibodies (MDA). This LUV was found to be equal to or better than that of conventional LAVs in efficacy. 20, 21 The success of this LUV indicates a potential approach to circumventing the MDA interference which is a problem in vaccination against multiple viral diseases.

As per this mechanism, the live vaccine virus is mixed with enough neutralizing anti-virus antibodies to form the virus-antibody immune complexes which inhibit the viral pathogenesis via three routes ( Figure 1 ):

blocking the virus to bind to its receptors on target cells, and thus blocking the viral entry and replication; 23-25 activating the complement system to destroy the virus, via the binding of the antibody Fc fragments to complement proteins; 26 presenting the virus to immune cells and aiding them to destroy the virus, via the binding of the antibody Fc fragments to the Fc receptors on the immune cells. [27] [28] [29] [30] [31] [32] The virus could be destroyed through antibody-dependent cell-mediated cytotoxicity (ADCC) of natural killer cells and antibody-dependent cellular phagocytosis (ADCP) of macrophages, dendritic cells, and other APCs. [27] [28] [29] In principle, AVA LUVs are applicable to all viruses except a few viruses, such as human immunodeficiency virus and African swine fever virus, [33] [34] [35] which can replicate efficiently in some immune cells carrying the Fc receptors, because AVA could aid the live pathogenic virus to enter and replicate in these cells through the Fc receptors.

The anti-virus antibodies used for AVA LUV production are from the plasma or serum of recovered or vaccinated homologous hosts, which are of limited supply and contamination risk. [16] [17] [18] [19] [20] [21] Humanized mAbs could be employed for production of AVA LUVs, because they can efficiently inhibit viral replication and aid complements and immune cells to destroy relevant viruses, and have been used successfully in the therapy of relevant viral diseases. 22, 24, 25, 30, 31 Moreover, production of humanized mAbs has been highly efficient with relatively low cost. 22, 25 One liter of CHO cell culture can produce 1-10 g/L humanized mAbs, 22 and thus ten liters of CHO cell culture could supply AVA for one million doses of an AVA LUV (<10µg/dose) . 9, 10 Therefore, this technology can rejuvenate AVA LUVs for preventing viral diseases.

To enhance the safety of LUVs based on humanized mAbs, it is better to use two or more humanized neutralizing mAbs targeting different epitopes for production of an AVA LUV, like simultaneous use of handcuffs and fetters to lock some people to safely prevent them to commit crimes.

This mechanism is the same as AVA, except that the involved antibodies are anti-glycan antibodies, which are naturally abundant in hosts, usually due to frequent antigenic stimulation of gastrointestinal bacteria carrying the glycans. 12, 36 Anti-glycan antibodies produced in humans target over 100 kinds of glycans, including α1,3-galactose (αGal) and N-5-glycolyl-neuraminic acid. 32, 37 Of these anti-glycan antibodies, anti-αGal antibodies (anti-αGal-Abs) are the most abundant in humans, constituting ~1% of serum IgG, IgM, and IgA immunoglobulins. 34, 37 Anti-αGal-Abs also exist as IgA and IgG in milk, colostrum, saliva, and bile. 38 Thus, anti-αGal-Abs are the most suitable for human AGA LUVs. 12, [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] Enveloped viruses replicating in cells of humans, apes, Old-World monkeys lack αGal glycans (αGal-Gs) because genomic mutations inactivated the enzyme α1,3Galactosyltransferase (α1,3GT) in these cells. 36, 39 In contrast, enveloped viruses replicating in cells replicating non-primate mammals, lemurs, or New-World monkeys carry αGal glycans (αGal-Gs), because these cells express active α1,3GT. 12, 36, 39 These viruses can bind to anti-αGal-Abs, and thus they can be used for producing AGA LUVs for humans.

Like AVA LUVs, AGA LUVs inhibit viral replication through the three routes: blocking the viral entry, aiding complements to destroy the virus, and aiding immune cells to destroy the virus (Figure 1 ). For example, in vitro incubation of eastern equine encephalitis virus carrying αGal-Gs with human anti-αGal-Abs blocked the replication of ∼50% of the virions in Vero cells, whereas such inhibition was not detected with the virus lacking αGal-Gs. 36, 42 It has been found that anti-αGal-Abs can aid complements to destroy over ten species of viruses carrying αGal-Gs, 36, [42] [43] [44] [45] [46] [47] [48] and aid immune cells to kill HIV-1 through ADCC and ADCP. 49 Multiple studies demonstrated that anti-αGal-Abs can even aid immune cells to kill cancer cells and play a key role in rejecting xenografts carrying αGal-Gs through ADCC. 36, 50 AGA LUVs have not been marketed for control of viral diseases, but anti-glycan antibodies probably have protected humans for millions of years against infectious diseases caused by viruses from non-primate animals. 12, [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] This protection process involves virus killing and viral antigen capture aided by AGA (Figure 1 ), and should induce certain acquired immunity against these viruses. Therefore, many people have been naturally inoculated with AGA LUVs against various viruses, although the doses might be too low to induce strong acquired immunity.

Although AGA LUVs can form the immune complexes in vivo post inoculation, the vaccine virus should be mixed with anti-glycan antibodies during the vaccine production, to ensure that the immune complexes of anti-glycan antibodies and the live vaccine virus are well formed in time in all vaccine recipients. 12, 36 Unlike anti-virus antibodies, anti-glycan antibodies are naturally available and can bind to many species of viruses, if they replicate in proper cell lines and present the target glycans. [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] However, their antiviral efficacy could be lower than that of neutralizing anti-virus antibodies. Therefore, AGA LUVs could cause diseases in some cases. Usually they should be used along with other safety mechanisms.

As per this mechanism, replication of the live vaccine virus is inhibited by an antiviral which could be a chemical, peptide, or medicinal herb. Unlike antibodies, the antiviral is unable to aid complements or immune cells to destroy the virus, but able to inhibit the viral entry, genome synthesis, protein cleavage, or virion assembly, and thus inhibits the virus replication ( Figure  1 ). 54 Antivirals have cured many people infected with viruses and help them acquire specific immunity against the viruses. Otherwise these people could have died of the infections. Therefore, many people have been naturally inoculated with NAA LUVs against various viruses with various safety and efficacy, although no NAA LUVs have been marketed.

Currently, around 90 non-antibody antivirals have been approved for the therapy of viral diseases. 55 With the computer modelling and other modern technologies, discovery and marketing of efficacious antivirals will be accelerated. 56, 57 This will offer more opportunities for development of NAA LUVs.

Notably, effective antivirals could be ineffective for curing patients with viral diseases. 13 This is because, for instance, an effective antiviral which can effectively inhibit the replication of SARS-CoV-2, could nor repair the damages in some organs caused by the viral replication. On the other side, complete inhibition of SARS-CoV-2 from the very beginning of the infection with an antiviral can prevent COVID-19, even if the antiviral has limited efficacy to repair the damages caused by the viral replication. Therefore, remdesivir and chloroquine phosphate could be used for COVID-19 NAA LUVs as they effectively inhibit the viral replication, although they are not highly effective for curing COVID-19 patients. 13, [58] [59] [60] NAA LUVs could cause diseases in some cases. Usually they should be used along with other safety mechanisms.

This mechanism has been applied safely for 40 years for preventing adenovirus-associated acute respiratory disease in US recruits, using two wild-type adenoviruses inoculated enterally to bypass the pathogenesis site of the lungs 13, 61, 62 . This ETI LUV safely reduced clinical cases caused by types 4 and 7 adenoviruses in US recruits by over 99% 62 .

Beyond enteral inoculation, we recently proposed that intramuscular inoculation of a respiratory virus could also reduce its pathogenesis ( Figure   2 ). 12 If the live vaccine is inoculated nasally, the vaccine live virus can attach directly to and replicate efficiently in its favourite cells. In contrast, if the live vaccine is inoculated intramuscularly, immune molecules and cells of the whole body, particularly those in the circulation system, could readily identify, capture, and destroy the injected virus. Therefore, the live virus could have limited chances to replicate in humans, and their limited replication is also inhibited by innate immunity of the whole body. To test this mechanism, mice were inoculated with 10^6 50% egg-infective dose (EID50) of H5N6 subtype of avian influenza virus through nasal and intramuscular administration. 12 All the mice inoculated nasally developed severe pneumonia and encephalitis with the mortality of 70%, while all the mice inoculated intramuscularly maintained health throughout the experiment and produced adequate immunity against nasal challenge with 10^8 EID50 of the same virus. 12 ETI is readily available but may be only suitable to respiratory viruses. ETI LUVs could cause diseases in some cases, and usually they should be used along with other safety mechanisms, except that their safety has been well confirmed through animal experiments and clinical trials

LUVs could have multiple important advantages over other vaccines.

(1) High safety. AVA LUVs using humanized neutralizing mAbs could be safer than LAVs, because the live virus is always bound with the neutralizing antibodies, like people locked in handcuffs and fetters. Therefore, they could be used in humans with immunodeficiency. This is supported by multiple studies showing that humanized neutralizing mAbs effectively blocked infection and suppressed viremia in rhesus macaques and humans with immunodeficiency. 30, 31 As demonstrated by the LUV for adenovirus infection, LUVs based on other safety mechanisms could also have adequate safety, particularly when two or more safety mechanisms are used simultaneously. Notably, animal experiments and clinical trials should be conducted to confirm whether a LUV is safe adequately. [9] [10] [11] [12] [13] (2) High efficacy. Usually, LAVs are more efficacious than inactivated vaccines and subunit vaccines, and LUVs could be more efficacious than This article is protected by copyright. All rights reserved.

LAVs, because their antigenic epitopes are the same as those of the wild-type viruses. This is supported by the experiments which showed that influenza LAVs based on rare codons without changes in antigenic epitopes were more efficacious than influenza cold-adapted LAVs with changes in antigenic epitopes. 63 High efficacy of some LUVs was also demonstrated by the fact that the past three influenza pandemics, which could be considered as mass vaccination with influenza LUVs, all eliminated one ingrained subtype of influenza virus sharing the same subtype or some genomic segments with the pandemic virus from humans. 64 Furthermore, AVA LUVs and AGA LUVs can enhance their efficacy through immune opsonization: via the binding of the antibody Fc fragments to the Fc receptors on APCs, the antibodies assist APCs to capture, process, and present relevant antigenic epitopes to T and B cells. 28, 32, [51] [52] [53] (3) High development speed. LUVs could be developed rapidly in many countries because they neither require time-consuming and technology-requiring attenuation of the virus, nor raise concern regarding pathogenic reversion. Development of AVA or NAA LUVs can be accelerated if relevant humanized neutralizing mAbs or effective antivirals have been available. AGA LUVs and ETI LUVs could be developed more rapidly, as these mechanisms are naturally available. 12 (4) High production efficiency. LUVs could be produced efficiently like LAVs. For instance, around 10 billion virions are required for producing one dose of inactivated influenza vaccine, and these virions could be used for producing 1,000 doses of LUVs or LAVs. 12, 63 (5) Avoiding vaccination pitfalls. Because LUVs could be highly efficacious, they have the potential to circumvent the vaccination risk of antibody-dependent enhancement (ADE), a major potential pitfall for vaccine development. 60, 65 ADE is a mechanism through which dengue viruses, feline coronaviruses, SARS coronavirus, and HIV viruses take advantage of low-levels of anti-viral antibodies to infect host cells. 65 Moreover, AVA LUVs and AGA LUVs could circumvent the interference of MDA, as indicated by the AVA LUV used for chicken infectious bursal disease. 20, 21 Meanwhile, the protection effect of MDA could be unaffected with inoculation of AVA LUVs, because the LUVs can be bound with neutralizing antibodies before inoculation, and the vaccine virus cannot replicate efficiently in vivo. This is different from LAV inoculation which usually consumes MDA significantly and thus reduces the protection effect of MDA against the relevant disease.

Consequently, LAV recipients could be more susceptible to the disease for some days after LAV inoculation than before the inoculation. This could be another reason why LUVs could be safer than LAVs.

With the above important advantages, LUVs could be powerful for controlling COVID-19. AVA LUVs for COVID-19 could be the safest and most efficacious. Currently, over 60 humanized neutralizing mAbs have been under investigation for the therapy of COVID-19, 3,23-25 greatly facilitating development of AVA LUVs for COVID-19. Because humanized mAbs are usually produced using murine CHO cells 22 , they carry αGal glycans and can bind to anti-Gal-Abs which are abundant in humans. 66 Moreover, the LUVs can be inoculated intramuscularly. Therefore, the AVA LUVs can simultaneously utilize the mechanisms of AGA and ETI, further securing the safety and efficacy of the vaccines.

The simplest COVID-19 LUVs rely on the mechanisms of AGA and ETI.

These LUVs could be as simple as intramuscular inoculation of live SARS-CoV-2 which is produced using porcine PK-15 cells and thus carries αGal-Gs. 12 It is highly recommended that, during the vaccine production, the live virus is mixed with AGA purified from human sera, to ensure that the immune complexes of AGA and SARS-CoV-2 are well formed in time. 12 Although AGA LUVs could be less safe than AVA LUVs, they could be safe adequately for COVID-19, and they can be developed and produced in much more countries with much higher efficiency. Notably, not only vaccine safety and efficacy, but also vaccine development speed and production efficiency are important for reducing deaths and losses caused by COVID-19. 13, 67 LUVs can be employed for prevention of other viral diseases, such as respiratory syncytial virus infection, the leading cause of viral lower respiratory tract infection in children. 69, 70 Tremendous efforts have not succeeded so far in marketing a vaccine for this disease. Multiple humanized neutralizing mAbs have been approved as therapeutics of this disease, and potential non-antibody antivirals against this virus have also been reported. 69, 70 These agents greatly facilitate development of AVA LUVs or NAA LUVs for this respiratory disease. Again, AVA LUVs could be the safest and most efficacious for this disease, and they could simultaneously utilize the mechanisms of AGA and ETI. The AVA LUVs could circumvent the ADE pitfall and the MDA interference, both of which have been observed with this disease. 68

This article elucidates that LUVs could be highly safe with selective use of neutralizing anti-virus antibodies, natural anti-glycan antibodies, non-antibody antivirals, and ectopic inoculation. It also suggests that LUVs could be of high efficacy, high development speed, and high production efficiency, with the aid of modern technologies. They could circumvent antibody-dependent enhancement and maternal-derived antibody interference. With these important advantages, LUVs could be more powerful than other vaccines for controlling some viral diseases, and they warrant urgent investigation using animal experiments and clinical trials for defeating the COVID-19 pandemic.

The work has not been supported by any funds. The author thanks Meng Yang and Jiwang Chen for their helpful assistance.

The authors declare there are no conflict of interests.

JMC conducted this study alone.

The data supporting the views of this article are available from the corresponding author on request.

The article does not contain the participation of animals and humans other than the authors.

World Health Organization. Coronavirus disease (COVID-2019) situation reports

World Health Organization. The power of vaccines: still not fully utilized

COVID-19 vaccine & therapeutics tracker

Progress and prospects on vaccine development against SARS-CoV-2

Vaccination against coronaviruses in domestic animals

SARS-CoV-2 mRNA vaccine development enabled by prototype pathogen preparedness

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Development of an inactivated vaccine candidate for SARS-CoV-2

Development of an inactivated vaccine candidate, BBIBP-CORV, with potent protection against SARS-CoV-2

Vaccines through centuries: major cornerstones of global health

World Health Organization. Immunization, vaccines and biologicals

SARS-CoV-2 replicating in non-primate mammalian cells probably have critical advantages for COVID-19 vaccines due to anti-αGal antibodies: A minireview and proposals

Potential of live pathogen vaccines for defeating the COVID-19 pandemic: history and mechanism

Identification of the mechanisms causing reversion to virulence in an attenuated SARS-CoV for the design of a genetically stable vaccine

Life-threatening infections due to live-attenuated vaccines: early manifestations of inborn errors of immunity

The yellow fever vaccine: a history

A yellow fever virus 17D infection and disease mouse model used to evaluate a chimeric Binjari-yellow fever virus vaccine

Food and Agriculture Organization

af4/DFID_impact_case_study_Rinderpest_April2010_1_.pdf

Rinderpest: the veterinary perspective on eradication

Infectious bursal disease virus in chickens: prevalence, impact, and management strategies

Comparative evaluation of HVT-IBD vector, immune complex, and live IBD vaccines against vvIBDV in commercial broiler chickens with high maternally derived antibodies

Advances in recombinant antibody manufacturing

Potently neutralizing and protective human antibodies against SARS-CoV-2

Human-IgG-neutralizing monoclonal antibodies block the SARS-CoV-2 infection

Antiviral monoclonal antibodies: can they be more than simple neutralizing agents?

Complement activation by IgG containing immune complexes regulates the interaction of C1q with its ligands

Update on Fc-mediated antibody functions against HIV-1 beyond neutralization

Immune complex vaccination

Converting monoclonal antibody-based immunotherapies from passive to active: bringing immune complexes into play

Antibody therapies for the prevention and treatment of viral infections

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117

From therapeutic antibodies to immune complex vaccines

Manipulation of dendritic cell function by viruses

Dengue virus infects macrophages and dendritic cells in a mouse model of infection

A seven-gene-deleted African swine fever virus is safe and effective as a live attenuated vaccine in pigs

Human natural antibodies to mammalian carbohydrate antigens as unsung heroes protecting against past, present, and future viral infections

Microbial glycan microarrays define key features of host-microbial interactions

Anti-alpha-galactosyl immunoglobulin A (IgA), IgG, and IgM in human secretions

Gene sequences suggest inactivation of

Galactosyltransferase in catarrhines after the divergence of apes from monkeys

Distribution of bacterial α1,3-galactosyltransferase genes in the human gut microbiome

Lytic anti-α -galactosyl antibodies from patients with chronic Chagas' disease recognize novel O-linked oligosaccharides on mucin-like glycosyl-phosphatidylinositol-anchored glycoproteins of Trypanosoma cruzi

Differential host dependent expression of α-Galactosyl glycans on viral glycoproteins: A study of Eastern equine encephalitis virus as a model

Sensitization of cells and retroviruses to human serum by α1-3 Galactosyltransferase

Evaluation of the Galα1-3Gal epitope as a host modification factor eliciting natural humoral immunity to enveloped viruses

Expression of ABO or related antigenic carbohydrates on viral envelopes leads to neutralization in the presence of serum containing specific natural antibodies and complement

A novel mechanism of retrovirus inactivation in human serum mediated by anti-α-Galactosyl natural antibody

The neutralization of pseudorabies virus by anti-α-Galactocyl natural antibody in normal serum

Xenoantigen-dependent complement-mediated neutralization of LCMV glycoprotein pseudotyped VSV in human serum

Neutralization of HIV-1 by redirection of natural antibodies

AGI-134: a fully synthetic α-Gal glycolipid that converts tumors into in situ autologous vaccines, induces anti-tumor immunity and is synergistic with an anti-PD-1 antibody in mouse melanoma models

Increased immunogenicity of influenza virus vaccine by anti-Gal mediated targeting to antigen presenting cells

Increased immunogenicity of HIV-1 p24 and gp120 following immunization with gp120/p24 fusion protein vaccine expressing α-Gal epitopes

The influence of natural antibody specificity on antigen immunogenicity

Drug targets for COVID-19 therapeutics: Ongoing global efforts

List of antiviral drugs

Bioengineering tools to speed up the discovery and preclinical testing of vaccines for SARS-CoV-2 and therapeutic agents for COVID-19

Accelerating Drug Development: Antiviral Therapies for Emerging Viruses as a Model

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Virology, pathogenesis, diagnosis and in-line treatment of COVID-19

COVID-19: immunopathology and its implications for therapy

Immunization with types 4 and 7 adenovirus by selective infection of the intestinal tract

Safety evaluation of adenovirus type 4 and type 7 vaccine live, oral in military recruits

Live-attenuated H1N1 influenza vaccine candidate displays potent efficacy in mice and ferrets

Potential for elimination of SAR-CoV-2 through vaccination as inspired by elimination of multiple influenza viruses through natural pandemics or mass vaccination

Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins

Lectin bio-layer interferometry for assessing product quality of Fc-glycosylated immunoglobulin G

Challenge trials-could deliberate coronavirus exposure hasten vaccine development?

The journey to a respiratory syncytial virus vaccine

De novo protein design enables the precise induction of RSV-neutralizing antibodies

RK-33 is a broad-spectrum antiviral agent that targets DEAD-Box RNA helicase DDX3X